Medpace Holdings, Inc. (MEDP)
Automate Your Wheel Strategy on MEDP
With Tiblio's Option Bot, you can configure your own wheel strategy including MEDP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MEDP
- Rev/Share 70.9705
- Book/Share 19.535
- PB 15.2061
- Debt/Equity 0.2134
- CurrentRatio 0.7319
- ROIC 0.5093
- MktCap 8537692280.0
- FreeCF/Share 17.8013
- PFCF 15.7834
- PE 21.6779
- Debt/Assets 0.0668
- DivYield 0
- ROE 0.5436
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MEDP | William Blair | Outperform | Market Perform | -- | -- | April 22, 2025 |
| Downgrade | MEDP | TD Cowen | Buy | Hold | -- | $328 | April 14, 2025 |
| Initiation | MEDP | Leerink Partners | -- | Market Perform | -- | $330 | March 24, 2025 |
| Downgrade | MEDP | Robert W. Baird | Outperform | Neutral | $413 | $349 | Oct. 23, 2024 |
| Initiation | MEDP | Redburn Atlantic | -- | Buy | -- | -- | Oct. 14, 2024 |
| Downgrade | MEDP | UBS | Buy | Neutral | $420 | $350 | Sept. 27, 2024 |
| Downgrade | MEDP | Jefferies | Buy | Hold | $415 | $345 | Sept. 25, 2024 |
News
CON vs. MEDP: Which Stock Is the Better Value Option?
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
Read More
CON or MEDP: Which Is the Better Value Stock Right Now?
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Analysts Estimate Medpace (MEDP) to Report a Decline in Earnings: What to Look Out for
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Negative
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
CON vs. MEDP: Which Stock Is the Better Value Option?
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical Services sector might want to consider either Concentra Group (CON) or Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Medpace Holdings: It Might Be Time To Buy In
Published: April 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Medpace has historically shown incredible growth and strong return metrics. It is currently down 35% from its ATH. The valuation has come down to more favorable levels. Risks include uncertainties around pharmaceutical spending and backlogs, which could make the current valuation appear too high.
Read More
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Medpace (MEDP) closed at $330.59 in the latest trading session, marking a +1.96% move from the prior day.
Read More
CON or MEDP: Which Is the Better Value Stock Right Now?
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
Read More
CON vs. MEDP: Which Stock Is the Better Value Option?
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Medpace (MEDP) Advances While Market Declines: Some Information for Investors
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Medpace (MEDP) concluded the recent trading session at $324.13, signifying a +1.55% move from its prior day's close.
Read More
An Investigation Has Been Launched Into Medpace Holdings, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 28, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
An Investigation Has Been Launched Into Medpace Holdings, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Medpace Holdings, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation
Published: February 17, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Medpace Holdings, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Medpace Holdings, Inc. (MEDP) Q4 2024 Earnings Call Transcript
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Medpace Holdings, Inc. (NASDAQ:MEDP ) Q4 2024 Earnings Conference Call February 11, 2025 9:00 AM ET Company Participants Lauren Morris - Director, Investor Relations August Troendle - Chief Executive Officer Jesse Geiger - President Kevin Brady - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Max Smock - William Blair Eric Coldwell - Baird David Windley - Jefferies Jailendra Singh - Truist Securities Justin Bowers - Deutsche Bank Charles Rhyee - TD Cowen Ann Hynes - Mizuho Operator Good day, ladies and gentlemen, and welcome to the Medpace Fourth Quarter and Full-Year 2024 Earnings Conference Call. At this …
Read More
Medpace (MEDP) Beats Q4 Earnings and Revenue Estimates
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Medpace (MEDP) came out with quarterly earnings of $3.67 per share, beating the Zacks Consensus Estimate of $2.97 per share. This compares to earnings of $2.46 per share a year ago.
Read More
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results
Published: February 10, 2025 by: Business Wire
Sentiment: Neutral
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Results Revenue for the three months ended December 31, 2024 increased 7.7% to $536.6 million, compared to $498.4 million for the comparable prior-year period. On a constant currency basis, revenue for the fourth quarter of 2024 increased 7.8% compared to the fourth quarter of 2023. Backlog as.
Read More
Medpace Holdings, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
About Medpace Holdings, Inc. (MEDP)
- IPO Date 2016-08-11
- Website https://www.medpace.com
- Industry Medical - Diagnostics & Research
- CEO Dr. August James Troendle M.D.
- Employees 5900